SCHEDULE: Wellington Management Discloses 6.8% Stake in Crinetics Pharmaceuticals

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 7,131,084 shares, representing approximately 6.8% of Crinetics Pharmaceuticals, Inc.'s common stock as of June 30, 2026.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed an amended Schedule 13G.
• The filing reports beneficial ownership of 7,131,084 shares of Crinetics Pharmaceuticals, Inc. common stock.
• This ownership represents approximately 6.8% of the class of securities outstanding as of June 30, 2026.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming stake by a major investment manager. The filing primarily confirms existing holdings and does not signal aggressive new activity.

Positives

• Confirms a substantial investment by a reputable investment management firm, Wellington Management, in Crinetics Pharmaceuticals.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a stable, long-term investment perspective rather than a short-term activist play.

Negatives

• The filing does not provide any new strategic information or performance data for Crinetics Pharmaceuticals itself, focusing solely on Wellington's holdings.

Risks

• Potential for future changes in Wellington Management's holdings, which could impact the stock price if significant buying or selling occurs.
• The concentration of ownership among a few entities within the Wellington group could lead to coordinated actions, though the filing states these are not for influencing control.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Crinetics Pharmaceuticals' future performance. It solely reports on the current beneficial ownership by Wellington Management entities.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate."

Industry Context

StockSavvy.ai notes that this filing is typical for large institutional investors like Wellington Management, which often hold significant stakes in publicly traded companies. The filing confirms their role as a substantial, passive investor in the biotechnology or pharmaceutical sector, where Crinetics Pharmaceuticals operates.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively as a sign of confidence in the company's prospects. However, it also implies potential for future stock price volatility if Wellington's holdings change significantly.

Next Steps

• Wellington Management will continue to hold its shares in Crinetics Pharmaceuticals in the ordinary course of business.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership exceeding reporting thresholds.

Key Dates

Keywords

Crinetics Pharmaceuticals, Wellington Management, Schedule 13G, Beneficial Ownership, Investment Holding, Common Stock, SEC Filing, Institutional Investor